Lilly Reports Results of Tirzepatide in P-lll SURPASS-3 and 5 Trials for Type-2 Diabetes
Shots:
- The P-lll SURPASS-3 study involves assessing Tirzepatide (5/10/15 mg) vs titrated insulin degludec in 1444 participants in a ratio (1:1:1:1) with T2D treated with metformin with or without an SGLT-2 inhibitor for 52wks.
- The P-lll SURPASS-5 study involves assessing Tirzepatide (5/10/15 mg) vs PBO in 475 participants in a ratio (1:1:1:1) in adults with inadequately controlled T2D already being treated with insulin glargine with or without metformin
- The SURPASS-3 & 5 shows A1C reduction: (-1.93% /-2.20%/-2.37% vs- 1.34%) & (-2.23%/-2.59%/ -2.59% vs -0.93%); Weight reduction: (-8.1%/ -11.4%/-13.9% vs +2.7%) & (-6.6%/-8.9%/-11.6% vs +1.7%) respectively
Ref: PRNewswire | Image: Fortune
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com